Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Multiple myeloma, gammopathies

Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Flow chart and survival analyses of the GMMG MM5 trial.

References

  1. 1.

    Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet. 2015;385:2197–208.

    Article  Google Scholar 

  2. 2.

    Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–40.

    Article  Google Scholar 

  3. 3.

    Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012;97:1925–8.

    Article  Google Scholar 

  4. 4.

    Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015;29:1721–9.

    CAS  Article  Google Scholar 

  5. 5.

    Goldschmidt H, Mai EK, Dürig J, Scheid C, Weisel KC, Kunz C, et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia. 2020;34:1853–65.

    CAS  Article  Google Scholar 

  6. 6.

    Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.

    CAS  Article  Google Scholar 

  7. 7.

    Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29–38.

    CAS  Article  Google Scholar 

  8. 8.

    Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936–45.

    CAS  Article  Google Scholar 

  9. 9.

    Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A, et al. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer. 2019;19:504.

    Article  Google Scholar 

  10. 10.

    Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, et al. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica. 2015;100:964–9.

    CAS  Article  Google Scholar 

  11. 11.

    Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, et al. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica. 2016;101:e485–87.

    CAS  Article  Google Scholar 

  12. 12.

    Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144:895–903.

    CAS  Article  Google Scholar 

  13. 13.

    Merz M, Dechow T, Scheytt M, Schmidt C, Hackanson B, Knop S. The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. Ann Hematol. 2020;99:1709–25.

    CAS  Article  Google Scholar 

  14. 14.

    Pawlyn C, Khan MS, Muls A, Sriskandarajah P, Kaiser MF, Davies FE, et al. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood. 2014;124:2467–8.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The GMMG-MM5 trial was supported by Celgene, Janssen-Cilag, Chugai, and The Binding Site. The GMMG thanks the Koordinierungszentrum für Klinische Studien (KKS) Heidelberg for the support of the trial and data monitoring. The GMMG thanks all participating investigators and centers.

Author information

Affiliations

Authors

Contributions

Conception and design: HS, MMe, HG, UB, KM, and AB. Responsible statisticians: KM and AB. Administrative support: HG, UB, and SPL. Provision of study materials or patients and/or collection, assembly and review of data: all authors. Data analysis and interpretation: HS, AE, MMe, HG, EKM, KM, and AB. Writing of the first manuscript draft: HS, AE, MMe, and HG. Manuscript editing, discussion of trial data/results, and final writing: all authors. Final approval of manuscript: all authors.

Corresponding author

Correspondence to Hans Salwender.

Ethics declarations

Conflict of interest

HS: honoraria: AbbVie, Amgen, BMS, Celgene, Chugai, GSK, Janssen, Oncopeptides, Sanofi, Sebia, Takeda; travel, accommodations, expenses: Amgen, BMS, Celgene, Janssen, Sanofi. AE: honoraria: Janssen, Celgene, Takeda; consulting or advisory role: Janssen, Amgen, Celgene, Takeda, Sanofi; travel, accommodations, expenses: Janssen, Takeda, Celgene, Amgen, Novartis. MMe: consulting or advisory role: BMS, Amgen, Takeda; research funding: Takeda; travel, accommodations, expenses: Celgen, AMGEN, Takeda, Abbvie, Janssen. KM: no COI AB: no COI MHä: honoraria: Novartis, Amgen, Roche, Takeda; consulting or advisory role: Celgene. CJ: honoraria: Janssen, Celgene, Takeda; consulting or advisory role: Janssen, Amgen, Celgene, Takeda, Sanofi; travel, accommodations, expenses: Janssen, Takeda, Celgene, Amgen, Novartis EKM: honoraria: Janssen, Celgene, Takeda, GSK; consulting or advisory role: Janssen, Celgene, Takeda, GSK; research funding: Takeda; travel, accomodations, expenses: Janssen, Takeda, Celgene, Onyx, BMS, Mundipharma. UB: no COI IWB: research funding: Celgene, BMS, Janssen. CS: honoraria: BMS, Janssen, Celgene, Novartis, Amgen, Takeda; consulting or advisory role: BMS, Janssen, Celgene, Novartis, Amgen, Takeda; speakers bureau: Takeda; research funding: Takeda, Novartis; travel, accommodations, expenses: BMS, Janssen, Celgene, Novartis, Amgen, Takeda. DH: consulting or advisory role: I. Lamkap Bio AG. Discoveric AG; research funding: Celgene AG. Sanofi. Engmab AG; travel, accommodations, expenses: Celgene. AS: consulting or advisory role: I. Lamkap Bio AG. Discoveric AG; research funding: Celgene AG. Sanofi. Engmab AG. AJ: no COI MSR: consulting or advisory role, travel support: BMS, Amgen, Incyte, Takeda, Novartis, Janssen, AbbVie, Sanofi, Roche; Research Funding: Amgen, Novartis, Sanofi SPL: no COI BB: honoraria: Janssen-Cilag, GSK, Takeda. MMu: honoraria: Janssen, BMS, Takeda, Celgene, Amgen, GSK, Sanofi-Genzyme; consulting or advisory role: Janssen, BMS, Takeda, Celgene, Amgen, GSK; research funding: BMS, Incyte; travel, accomodations, expenses: Janssen, BMS, Takeda, Amgen. PB: consulting or advisory role: BMS, AMGEN, Roche, MSD; research funding: BMS; travel, accommodations, expenses: BMS. SF: consulting or advisory role: Amgen, BMS, Celgene, Sanofi, Janssen. H-WL: no COI KW: Grants from Amgen, Celgene, Sanofi, Janssen (all to the institution), honoraria and advisory board from Amgen, BMS, Celgene, Adaptive Biotech, Janssen, GSK, Karyopharm, Roche, Sanofi, Takeda, Oncopeptides. JD: consulting or advisory role: Celgene; speakers bureau: Celgene; travel, accommodations, expenses: Celgene. HG: Grants and/or provision of Investigational Medicinal Product: Amgen, BMS, Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, Sanofi. Research Support: Amgen, BMS, Celgene, Chugai, Janssen, Incyte, Molecular Partners, Merck Sharp and Dohme (MSD), Sanofi, Mundipharma GmbH, Takeda, Novartis. Advisory Boards: Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, Takeda. Honoraria: Amgen, BMS, Celgene, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Salwender, H., Elmaagacli, A., Merz, M. et al. Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. Leukemia (2021). https://doi.org/10.1038/s41375-021-01298-y

Download citation

Search

Quick links